文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

寡转移及寡复发性宫颈癌的挽救性再放疗

Salvage (Re)radiation in Oligometastatic and Oligorecurrent Cervical Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-07-16

该研究纳入2017至2020年连续接受放疗(联合或不联合全身化疗)的寡转移或寡复发宫颈癌患者58例,中位无进展生存期16个月,中位总生存期28个月,19%患者出现≥3级毒性,未发现预测总生存的因素。

要点

  • 58例寡转移或寡复发宫颈癌患者接受放疗(联合或不联合化疗),中位无进展生存期16个月,中位总生存期28个月。
  • 首次复发时34.4%为局部区域复发,32.8%为远处淋巴结转移,32.8%为内脏转移。
  • 19%患者出现≥3级毒性,单因素分析未发现预测总生存的患者或治疗相关因素。

核心结论

  • 在局部区域或远处寡复发或寡转移部位使用潜在根治剂量的放疗(包括再放疗),与宫颈癌患者令人鼓舞的无进展生存期和总生存期相关。

研究设计与样本

  • 研究纳入2017年至2020年期间连续接受放疗(联合或不联合全身化疗)的寡转移或寡复发宫颈癌患者58例,所有患者均接受全身化疗会诊及针对复发或转移部位的放疗。
  • 采用Kaplan-Meier法和log-rank检验评估各种预后及预测因素的作用。

主要发现

  • 58例患者的中位复发时间为18个月(范围8-205个月)。
  • 首次复发时,34.4%的患者(n=20)为局部区域复发,32.8%(n=19)为远处淋巴结转移,32.8%(n=19)为内脏转移。
  • 复发部位在既往照射野内者占34.5%(n=20),野外占50%(n=29),两者兼有占15.5%(n=9)。
  • 总体56%的患者(n=33)接受了全身化疗;再治疗时放疗剂量按2 Gy等效剂量为44 Gy(范围31-68 Gy)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with recurrent or metastatic cervical cancer, the median survival time is 13 to 24 months based on the choice of palliative systemic chemotherapy. Evolving evidence suggests that the addition of radiation may lead to improved survival. METHODS AND MATERIALS: Consecutive patients treated with radiation with or without systemic chemotherapy for oligometastatic or oligorecurrent disease within the period from 2017 to 2020 were included. All patients received systemic chemotherapy consultation and radiation to relapsed or metastatic sites. Progression-free survival (PFS) was determined as the period between diagnosis of relapse or metastasis and the last progression of the disease. Overall survival (OS) was defined as the time between the date of diagnosis of relapse or metastasis and follow-up or death. The effect of various prognostic and predictive factors was estimated using the Kaplan-Meier method and log-rank test. RESULTS: Fifty-eight consecutive patients were included. The median time to relapse was 18 months (8-205 months). At the time of first relapse, 34.4% of patients (n = 20) had locoregional relapse, 32.8% (n = 19) had distant nodal metastases, and 32.8% (n = 19) had visceral metastases. The relapse was within previously irradiated portals in 34.5% (n = 20), out of field in 50% (n = 29), and both in 15.5% (n = 9) of patients. Overall, 56% of patients (n = 33) received systemic chemotherapy. The radiation therapy dose in equivalent doses of 2 Gy at the time of retreatment was 44 Gy (31-68 Gy). The median PFS and OS from the date of first relapse were 16 (12-19) and 28 months (2-108), respectively. Grade ≥3 toxicity was observed in 19% of patients. No patient- or treatment-related factor was identified as predictive of OS on univariate analysis. CONCLUSIONS: The use of potentially radical doses of radiation, including reirradiation at locoregional or distant oligorelapse or metastasis, is associated with encouraging PFS and OS in patients with cervical cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Chopra S, Kalra B, Mulani J, et al. Salvage (Re)radiation in Oligometastatic and Oligorecurrent Cervical Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 35850364. doi:10.1016/j.ijrobp.2022.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。